Skip to content
Wired News Engine – Lifestyle
Author:
Monopar Therapeutics Inc.
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
June 1, 2026
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
April 19, 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 27, 2026